Adicet Bio ADI-001 Interim Clinical Data Call

Mr. Schor has served as Adicet’s President, Chief Executive Officer and Director since its merger with resTORbio in September 2020. He held the role of President and Chief Executive Officer at resTORbio since co-founding the company in 2016. Mr. Schor has led biotech companies across all stages, from formation and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL). Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds an M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

Dr. Galimi joined Adicet in September 2019 as Senior Vice President and Chief Medical Officer. He joined Adicet from Amgen, Inc., where he served as Global Program General Manager, Early Development. During his tenure at Amgen, he was responsible for the cross-functional strategy and execution of a portfolio of oncology programs, from pre-IND to late-stage. While at Amgen, he also served in a number of roles of increasing responsibility in clinical research and early development. Prior to Amgen, Dr. Galimi was the Head of Clinical Development at Onyx Pharmaceuticals, Inc., where he led the Oncology Clinical Development Group. He also served in leadership roles at GNF/Novartis leading the early development of a portfolio of oncology programs. Dr. Galimi holds a M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. from the University of Torino Medical School.

Dr. Neelapu's laboratory is focused on characterization of immune-regulatory mechanisms in the tumor microenvironment in patients with lymphoma and development of novel therapeutic strategies for patients with lymphoma. Dr. Neelapu obtained his medical degree in India and subsequently moved to the United States of America where he completed residency in Internal Medicine at Coney Island Hospital, Brooklyn, New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.